On May 23, 2022 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, reported that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference (Press release, Aldeyra Therapeutics, MAY 23, 2022, View Source [SID1234614961]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Brady’s conversation with Matthew Caufield, Vice President, Equity Research for H.C. Wainwright, will be available on demand beginning at 7:00 a.m. ET Tuesday, May 24, 2022. To view the webcast, log in to the Investors & Media section of the Aldeyra Therapeutics website at View Source The event will remain archived on the website for 90 days.